FHTX Stock Forecast: Foghorn Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$1.78
−0.56% on the day

The 10 Wall Street analysts covering Foghorn Therapeutics, Inc. hold a median 12-month price target of $5 — +180.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 56 of 100 as at 18 Nov 2026 — in the upper half.

Market cap
$109.7M
Ticker Nerd rank
56/ 100
Median analyst target
$5.00
Analysts covering
10
Revenue$16.1M+112.7% y/y
Operating income−$8.8M
Net income−$7.2M
Free cash flow−$17.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.2%
1M
−4.8%
YTD
−67.0%
1Y
−63.4%
From 52W high
−74.8%
From 52W low
0.0%
$1.78
$7.07
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Foghorn Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
56/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Revisions
82
Volatility
68
Quality
66
Value
34
Accruals
28
Momentum
16
Issuance
14

Growth (99): Sales and profits are climbing, and climbing faster than before.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

FHTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on FHTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$1.00$2.00$3.00$4.00$5.00$6.00$7.00Jan 26Apr 26Jul 26Oct 26FHTXHigh $5.00Median $5.00Low $2.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
5
Buy
5
Hold
0
Sell
$2.00
Low
$5.00
Median
$5.00
High

The green dot is the last close — the median target sits +180.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
2 Oct 2026BTIGDowngradeNeutral—
2 Oct 2026GuggenheimMaintainsBuy$12 → $5.00
2 Oct 2026HC Wainwright & Co.MaintainsBuy$13 → $5.00
2 Oct 2026TD CowenDowngradeHold—
2 Oct 2026WedbushDowngradeNeutral$10 → $2.00
12 Mar 2026WedbushReiteratesOutperform$10
10 Mar 2026HC Wainwright & Co.ReiteratesBuy$13
17 Feb 2026JefferiesMaintainsBuy—
18 Dec 2025BTIGInitiatesBuy—
4 Dec 2025StifelInitiatesBuy—
7 Nov 2025GuggenheimInitiatesBuy—
15 May 2025JMP SecuritiesReiteratesMarket Outperform—
30 Apr 2025HC Wainwright & Co.ReiteratesBuy—
30 Apr 2025JMP SecuritiesReiteratesMarket Outperform—
23 Apr 2025JMP SecuritiesInitiatesMarket Outperform—
7 Mar 2025HC Wainwright & Co.ReiteratesBuy—
30 Jan 2025B. Riley SecuritiesInitiatesBuy—
17 Dec 2024HC Wainwright & Co.ReiteratesBuy—
16 Dec 2024JefferiesMaintainsBuy—
24 Sept 2024Morgan StanleyMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for FHTX.

Market Radar

This page is one stock. Monday covers all of them.

FHTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

FHTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Foghorn Therapeutics, Inc. returned −63.4% against +9.2% for the S&P 500, dividends included.

FHTX vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26FHTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

FHTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.4×

Cheaper than 47% of US stocks

Price / sales
0.9×

Cheaper than 68% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
8.0%

Higher than 60% of US stocks

Net margin
—
Returns & dividend
Return on equity
—
Return on assets
2.8%

Higher than 63% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Foghorn Therapeutics, Inc. has a market value of $109.7M.

  • Revenue in the twelve months to 30 June 2026: $36.7M. The latest quarter grew 112.7% year on year.

  • Net income over the same four quarters: −$64.6M, a −175.8% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$84.3M.

  • Shares outstanding: 58.7M.

  • Trailing P/E: 19.4×.

  • Foghorn Therapeutics, Inc. employs 106 people — $347K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

FHTX and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
FHTXFoghorn Therapeutics, Inc.$109.7M56
CBUSCibus, Inc.$104.4M27
UNCYUnicycive Therapeutics, Inc.$104.2M36
TLSATiziana Life Sciences Ltd. (Bermuda)$103.7M25
ICCCImmuCell Corp.$102.3M94
GNLXGenelux Corp.$107.7M14
NERVMinerva Neurosciences, Inc.$108.6M28

Take a look at FHTX’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Foghorn Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about FHTX

What is the FHTX stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Foghorn Therapeutics, Inc. have a median 12-month price target of $5, with estimates ranging from $2 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is FHTX stock a buy right now?

Of the 10 analysts covering Foghorn Therapeutics, Inc., 5 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Foghorn Therapeutics, Inc. 56 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank FHTX?

As at 18 Nov 2026, Foghorn Therapeutics, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will FHTX stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +180.9% from the last close, and Ticker Nerd's factor model ranks Foghorn Therapeutics, Inc. 56 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the FHTX stock forecast for 2030?

No analyst covering Foghorn Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for FHTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $5 over the next 12 months.

How has FHTX stock performed over the past year?

Foghorn Therapeutics, Inc. returned -63.4% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Foghorn Therapeutics, Inc. do?

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that correct abnormal gene expression. Foghorn Therapeutics Inc. uses its proprietary Gene Traffic Control platform to study the chromatin regulatory system, a core mechanism that influences how genes are activated or silenced in cells.

Company

About Foghorn Therapeutics, Inc.

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that correct abnormal gene expression. Foghorn Therapeutics Inc. uses its proprietary Gene Traffic Control platform to study the chromatin regulatory system, a core mechanism that influences how genes are activated or silenced in cells. Its current programs are centered on oncology, with efforts directed at genetically defined cancers and other serious diseases linked to chromatin-driven dependencies. The company’s research and development activities include precision therapeutics designed to identify and validate drug targets within this regulatory network, supporting the creation of targeted treatments for hard-to-address diseases. Headquartered in Watertown, Massachusetts, Foghorn Therapeutics Inc. plays a specialized role in the biotechnology market as a developer of novel, mechanism-based therapies.

CEO Mr. Adrian H. B. Gottschalk · 106 employees · United States · https://foghorntx.com